Pfizer has found a new home for an early-stage antibody-drug conjugate (ADC) it gained through its $43-billion takeout of Seagen — then subsequently binned — according to a US securities filing from Medicus Pharma on Wednesday. In March, the pharma terminated a Phase I trial of PF-08046031 (SGN-CD228A) in patients with melanoma and other solid tumours, citing "strategic reasons." The melanotransferrin (CD228)–targeting candidate is one of more than a half-dozen Seagen-sourced ADCs that Pfizer h

US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity. The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and Company, Gaingels, Insight Partners, Nvidia, and RA Capital Management. The company plans to use the pr

GSK is spending up to $1.3 billion on a first-of-its-kind cancer therapy slated to enter the clinic this year. In a deal announced Thursday, GSK agreed to pay Hutchmed $110 million up front, and potentially roughly $1.19 billion more in milestone payments and royalties, for a majority of the rights to a treatment known as HMPL-A830. That treatment is what Hutchmed refers to as an “antibody-targeted therapeutic conjugate,” and could potentially address multiple tumor types. Typical antibody-dru

The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA) U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation, providing enhanced agency engagement throughout development and eligibility for accelerated approval and priority review Phase 3 design fully aligned with FDA; Biologics License Application (BLA) filing anticipated in 2028 OCU410 is designed as a one-time subreti

Signatera demonstrates 100% positive predictive value for treatment response assessment, detects recurrence months earlier than imaging, and supports precise, individualized lymphoma management through serial ctDNA monitoring Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile– –New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life Sept. 01, 2026 -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biot

Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission Sept. 01, 2026 -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs

Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure patients can access treatment in the community setting, where the majority of decompensated patients are managed RTX001 has the potential to be the first treatment that demonstrates a clear and durable improvement in transplant free survival for ESLD patients Sept. 01, 2026 -- Reso

– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company’s Phase 3 strategy is designed to deliver best-in-class efficacy across both indications by evaluating a high-dose, quarterly regimen of verekitug in broad patient populations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – Sept. 01, 2026 -- Upst

Roivant Sciences' Pulmovant subsidiary announced that its once-daily, inhaled soluble guanylate cyclase (sGC) activator mosliciguat cleared a mid-stage study, delivering a notable reduction in pulmonary vascular resistance (PVR) over placebo in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings were unveiled Tuesday at the European Respiratory Society (ERS) congress, sending Roivant's shares up nearly 29% in premarket trading. Pulmovant CEO Drew Fromkin said